“…1 illustrates a timeline of testing, symptom onset, and initiation of medical therapy for our two patients. We reviewed the literature for cases with reported ocular MPox and found 15 additional cases to date [4] , [5] , [6] , [7] , [8] , [9] , [10] , [11] , [12] , [13] , [14] . The spectrum of ophthalmic MPox manifestations, which include blepharitis, conjunctivitis, focal conjunctival lesions, corneal ulcerations, photophobia, keratitis, corneal scarring, and visual loss is summarized in the Table 1 [2] , [3] .…”